Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $0.50 → $0.53 | Underweight | Morgan Stanley |
| 11/16/2021 | $2.50 → $2.00 | Buy | HC Wainwright & Co. |
| 10/21/2021 | $4.00 → $2.50 | Buy | HC Wainwright & Co. |
| 10/14/2021 | $0.80 | Equal-Weight → Underweight | Morgan Stanley |
| 8/12/2021 | $3.00 → $1.00 | Equal-Weight | Morgan Stanley |
4 - Evofem Biosciences, Inc. (0001618835) (Issuer)
4 - Evofem Biosciences, Inc. (0001618835) (Issuer)
5 - Evofem Biosciences, Inc. (0001618835) (Issuer)
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. ("Pearsanta"), public via a proposed initial public offering ("IPO") in 2025. This decision aligns with Aditxt's mission to secure and develop transformative health innovations, positioning them for accelerated growth and broader market impact. Pearsanta, a precision diagnostic company, has advanced its development and operational capabilities, particularly in early cancer detection, by leveraging its proprietary Mitomic® Tec
Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. ("Adimune"), has successfully completed all preclinical efficacy and safety studies for its antigen-specific gene therapy, ADI-100. This achievement represents a major milestone as Adimune prepares to submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application to initiate first-in-human clinical trials for ADI-100 in the treatment of Type
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.'s ("Evofem") (OTCQB:EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substit
8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Underweight and set a new price target of $0.53 from $0.50 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.00 from $2.50 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.50 from $4.00 previously
SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)
SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)
SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)
Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice
Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as
SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023. Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Bioscien